KittisakJirasittichai / iStockphoto.com
The European Commission’s proposed export waiver for supplementary protection certificates has exposed a number of likely flaws which have not gone down well with patent owners. LSIPR reports.
Striking the perfect balance between incentivising innovation in drug development and widening access to medicines through generic competition is perhaps an unobtainable aim, but it’s an ideal that legislators and regulators must strive towards.
In 2016, in its “Resolution in the Single Market Strategy”, the European Parliament urged the European Commission to boost competition in the generic and biosimilar drugs market—without undermining the market exclusivity granted to IP owners—by 2019.
In response, in May this year, the Commission announced its plan to introduce a manufacturing waiver in relation to Regulation 469/2009, which governs the grant and scope of supplementary protection certificates (SPCs).
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
European Commission, supplementary protection certificate, patent, waiver, safeguard, market exclusivity, generic manufacturing, drug competition